Search research articles
Contact Us
Filters
Showing results (31-40 of 33) with videos related to
Page
of 4
Sort By:
You have reached the last page of results.
This site can display upto 33 results.
Journal of Bone Oncology
|
January 24, 2020
Patterns of care for patients with metastatic bone disease in solid tumors: A cross-sectional study from Switzerland (SAKK 95/16)
Michael Mark, Beat Thürlimann, Karin Ribi, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 19, 2011
Outcome, quality of life and cognitive function of patients with brain metastases from non-small cell lung cancer treated with whole brain radiotherapy combined with gefitinib or temozolomide. A randomised phase II trial of the Swiss Group for Clinical Cancer Research (SAKK 70/03)
Gianfranco A Pesce, Dirk Klingbiel, Karin Ribi, et al.
BMC Cancer
|
October 12, 2016
SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial
Christoph Rochlitz, Martin Bigler, Roger von Moos, et al.
Page
of 4
Search research articles
Search
Showing results (31-40 of 33) with videos related to
Sort By:
Page
of 4
You have reached the last page of results.
This site can display upto 33 results.
Journal of Bone Oncology
|
January 24, 2020
Patterns of care for patients with metastatic bone disease in solid tumors: A cross-sectional study from Switzerland (SAKK 95/16)
Michael Mark, Beat Thürlimann, Karin Ribi, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 19, 2011
Outcome, quality of life and cognitive function of patients with brain metastases from non-small cell lung cancer treated with whole brain radiotherapy combined with gefitinib or temozolomide. A randomised phase II trial of the Swiss Group for Clinical Cancer Research (SAKK 70/03)
Gianfranco A Pesce, Dirk Klingbiel, Karin Ribi, et al.
BMC Cancer
|
October 12, 2016
SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial
Christoph Rochlitz, Martin Bigler, Roger von Moos, et al.
Page
of 4